We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Validation Study of CD133 as a Reliable Marker for Identification of Colorectal Cancer Stem-Like Cells.
- Authors
You, C. Z.; Xu, H.; Zhao, F. S.; Dou, J.
- Abstract
Colorectal carcinoma (CRC) is maintained by putative colorectal cancer stem-like cells (CRC-CSCs) that are responsible for CRC metastasis and relapse. Targeting these CSCs can be an effective treatment of CRC. However, reliable identification of CRC-CSCs remains controversial due to the absence of specific markers. It is assumed that glycoprotein CD133 can serve as a useful marker for identification of CRC-CSCs. In this study, we employed CD133 as a marker to identify CRC-CSCs in human (LoVo, HCT116, and SW620) and mouse (CT26) CRC cell lines. In these lines, CD133+ cells were isolated and identified by magnetic-activated cell sorting and flow cytometry. Proliferation, colony formation, and drug resistance of CD133+ cells were analyzed in vitro, and their tumorigenicity was determined in vivo on mice. Proliferation, colony-forming ability, drug resistance, and tumorigenicity of CD133+ cells were higher than those of CD133– cells. Thus, cultured CD133+ cells had the characteristics of CSCs. Hence, glycoprotein CD133 is a reliable marker to identify CRC-CSCs. These results can be used for designing a novel therapeutic target in CRC treatment.
- Subjects
COLORECTAL cancer; CANCER cells; DRUG resistance; CELL culture; CANCER stem cells
- Publication
Bulletin of Experimental Biology & Medicine, 2024, Vol 176, Issue 3, p369
- ISSN
0007-4888
- Publication type
Article
- DOI
10.1007/s10517-024-06026-x